Advicenne announced on Monday the commercial launch of Sibnayal in Denmark, where the drug will be reimbursed by the social security system.

The pharmaceutical company reports that its partner in the country, FrostPharma, has been marketing this treatment for distal renal tubular acidosis (dRTA) since March 1, after obtaining pricing and reimbursement conditions from the Danish authorities.

The latter recognized that Sibnayal's therapeutic contribution was adapted to the medical need in the absence of therapeutic alternatives, and justified an annual treatment cost of close to 15,000 euros per patient.000 euros per patient.

Didier Laurens, CEO of Advicenne, believes that the Danish authorities' decision 'shows the way' for other European countries still discussing reimbursement conditions.

At FrostPharma, CEO Fredrik Andersch says that his ambition is to make Sibnayal available for adults and children with rare kidney diseases in all northern European countries.

Copyright (c) 2023 CercleFinance.com. All rights reserved.